ACP3 and posterior cortical atrophy: Currently, the only FDA-approved immunotherapy for the treatment of advanced PCa is Sipuleucel-T, an autologous cellular immunotherapy thought to work via antigen-presenting cell-induced stimulation of the T-cell immune response against prostatic acid phosphatase, an antigen expressed in PCa.16–18 The success with Sipuleucel-T has been limited thus far and overall clinical benefit in the current era of novel therapies has not be well defined.